207_Combined course Presentations

Prodige/ACCORD 12/0450 trial

Staging :- Evaluated by TRUS and/or MRI

Centre policy

S

Capecitabine 800mg/m2

45 Gy CRT

N=598

Oxaliaplatin 50mg/m2 x 5

S

Centre policy

Capecitabine 800mg/m2 *

50.4Gy CRT

Primary end point- pCR 11% - 20% 85% power